Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

The Chicago-based firm earlier announced that its two Phase II EMPOWER trials investigating emraclidine as a once-daily, oral ...

US company IDEAYA Biosciences has exercised the option for an exclusive worldwide license for Biocytogen Pharmaceuticals’ ...

Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III ...

On November 8, the US Food and Drug Administration approved Aucatzyl (obecabtagene autoleucel; obe-cel) from US biopharma Autolus Therapeutics, whose share rose more than 8% to 44.03 on the news.

The US trade group Pharmaceutical Research and Manufacturers of America (PhRMA) today launched new advertisements urging ...

Geron Corporation has secured $375 million to support the US and potential EU launch of Rytelo and pipeline development. The ...

Danish patients are being offered fewer innovative treatments than Norwegians and Swedes, a new estimate from the Danish Medicines Council shows. A calculation from the Medical Council shows that out ...

Sarepta Therapeutics (Nasdaq: SRPT) has announced it will cease development of SRP-5051, an experimental drug for Duchenne ...

The US Food and Drug Administration (FDA) plays a pivotal role in fostering the development of treatments for rare diseases ...

Danish allergy immunotherapy specialist ALK Abello has entered into a strategic license agreement with US-based ARS ...

Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi ...